New strategy aims to outsmart resistant prostate cancer
NCT ID NCT02703623
Summary
This study is testing different combinations of approved drugs to find better ways to control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It involves 196 men and uses a personalized approach: after an initial 8-week treatment, patients are assigned to different drug combinations based on how well their cancer markers respond. The main goals are to see if these combinations help patients live longer and to understand their side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson in Katy
Houston, Texas, 77094, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.